A b s t r a c t
Introduction
In spite of a steady decline over the last decades, gastroesophageal adenocarcinomas are still the fourth most common cancer and the second most common cause of cancer death worldwide, with more than 900,000 new cases and 700,000 deaths per year [1, 2] . In the absence of metastatic disease, surgical resection with negative microscopic margins is the only potentially curative treatment. Whereas patients with early-stage tumours have a 5-year survival rate of over 90% [3] , recurrence compromises about 80% of patients with locally advanced disease [4] . Consequently, for these tumour stages 5-year survival rates after primary surgery without multimodal therapy do not exceed 25-30% [5] . Recently, two randomised controlled trials have demonstrated that perioperative chemotherapy consisting of a neoadjuvant and postoperative cisplatin-and 5-FU based treatment regimen significantly improves progression-free and overall survival in patients with advanced gastric or lower oesophageal adenocarcinoma. The neoadjuvant chemotherapy proved to decrease tumour size and stage [6, 7] . The improvement of prognosis is most likely due to improved resectability following the downstaging of the tumour, the elimination of micrometastases, and the improvement of tumour-related symptoms. Commonly, patients with UICC stages II and III (UICC 2003), i.e. patients in whom the tumour shows serosa invasion and/or lymph node involvement, are considered eligible for neoadjuvant treatment. In order to identify these patients reliable staging is of utmost importance [8] .
Endoscopic ultrasound (EUS) has been considered as a valuable tool for the assessment of tumour invasion and locoregional lymph node status [9] . The diagnostic accuracy in T (tumour) staging and the specificity for assessing the serosal involvement of tumours shows comparable results to multidetector row computed tomography or magnetic resonance imaging [10] . However, due to technical particularities and inter-and intra-observer variability [11] , the value and accuracy of EUS for the pre-therapeutic stratification of gastroesophageal adenocarcinoma remains controversial. Reliable prediction of tumour extension often depends on histopathological features, tumour size and the localization of tumours [12] . Recent studies demonstrated a lower than expected concordance between EUS and histopathology results, ranging for all T (tumour) stages combined from 35 to 80% and for N (nodal) stages from 42 to 78% [13] [14] [15] .
Aim
This study presents our experience with EUS in the pre-therapeutic staging of gastroesophageal adenocarcinomas with the specific aim of assessing the diagnostic value of EUS for defining patients eligible for neoadjuvant chemotherapy.
Material and methods
Consecutive patients (n = 47) who underwent elective resection with curative intention for primary adenocarcinoma of the stomach, gastroesophageal junction and lower oesophagus at our department between January 2006 and June 2007 and who would have been eligible for neoadjuvant chemotherapy based on performance status and co-morbidities were included in this study. In June 2007 neoadjuvant chemotherapy became the consented standard therapy for locoregionally advanced disease at our institution. Single patients who had received neoadjuvant therapy before that date as an individual treatment decision were excluded from the analysis.
Endoscopic ultrasound was carried out at the Endoscopic Unit of the Department of Surgery. If biopsies of the lesion were still needed to confirm the diagnosis, they were done after EUS to avoid falsification of staging results. EUS was performed by using a rotating sector scan echoendoscope (Olympus GIF-UM20; 7.5-12 MHz) after filling the stomach with approximately 600 ml of water. The assessment of the ultrasound images was carried out at the time of the procedure by only two surgical endoscopists (PC, GK). Local tumour infiltration was determined according to the five-layer structure of the gastric wall and classified by using the TNM system (6 th edition, 2003) as recommended by the UICC and expressed by the values uT1-uT4. Lymph nodes were classified as metastatic (uN+, uNpositive) in accordance with generally accepted criteria or as without metastasis (uN0, uNnegative) [16, 17] . Besides EUS, hydro-CT of the stomach, abdominal ultrasound, and a chest radiograph were additionally used in order to exclude disseminated disease (stage IV disease with peritoneal or haematogenous tumour spread). Surgical treatment for all patients was subtotal or total gastrectomy with D2-lymphadenectomy, transhiatal extended total gastrectomy or abdomino-thoracic resection of the oesophagus.
The results of the EUS staging were compared with histopathological results obtained from the surgical specimen, which were considered "gold standard". The pathological assessment was performed using the standard TNM classification system (UICC TNM Atlas, 6 th edition 2002). Pathologists were unaware of EUS results at the time of performing the histopathological examination. For analysis and comparability with appropriate literature, the endosonographic uT2a category was considered as T2 whereas the uT2b category was included in the T3 group. Furthermore, pN1-3 stage was considered as one category, pN+ (pNpositive).
T and N stage concordance between EUS and pathological results were assessed. The percentage of cases for which EUS yielded under-and overstaging were calculated for each T and N category. Furthermore, regarding the accuracy of EUS as a method to decide on enrolment of patients in a neoadjuvant chemotherapy regimen, the sensitivity, i.e. the probability of correctly detecting patients eligible for neoadjuvant chemotherapy with EUS, and specificity, i.e. the probability of correctly detecting patients not eligible for neoadjuvant chemotherapy with EUS, were calculated. In addition, we determined the positive predictive value as the probability that a patient who was considered eligible for neoadjuvant chemotherapy based on EUS indeed showed histopathological serosal or lymph node invasion, and the negative predictive value as the probability that a patient who was not considered eligible for neoadjuvant chemotherapy based on EUS indeed showed no histopathological serosal or lymph node invasion. In the analyses, patients were hypothetically considered eligible for neoadjuvant therapy if the histopathological tumour stage was pT2b to pT4 and/or pN+ (pNpositive).
Results
In 37 of 47 patients (78.7%) EUS evaluation was possible (12 women, 25 men, median age 70.5, range 35.2-86 years). In 2 of 47 patients (4.3%), EUS was performed but meaningful T staging was not possible due to tumour stenosis. In 8/47 patients (17.0%) EUS was not performed because of logistic difficulties or patients' wish to undergo surgery regardless of any staging results.
Tumours were located in the distal oesophagus (n = 7; 19%), the gastroesophageal junction (n = 8; 22%) and the stomach (n = 22; 59%), respectively. Tables I and II show the distribution of uT and uN staging results and the corresponding histopathological stage. There were no uT4 or pT4 tumours in this study population.
Tables III and IV show the accuracy of EUS staging for the single uT and uN categories in terms of correct staging, understaging and overstaging as compared with the histopathological staging.
The overall accuracy for correctly predicting the pT stage with EUS was 64.9%. Preoperative overstaging of the pathological T stage was seen more frequently (21.6%) than understaging (13.5%). The overall accuracy for correctly predicting the pN stage was 64.7%. The accuracy for rightly determining nodal positivity with EUS was 50%, i.e. understaging of the preoperative N stage was seen in 50% of cases. In this study population 25 out of 37 patients would have met the eligibility criteria for enrolment in a neoadjuvant chemotherapy protocol based on postoperative histopathological results (T stage ≥ p2b and/or pNpositive). The sensitivity was 76% (n = 19/25). The specificity was 75% (n = 9/12). The positive predictive value was 86.4%. The negative predictive value was 60%.
Discussion
The overall mortality of gastroesophageal cancer remains substantial. Patients with locally advanced gastroesophageal cancer, who are at significant risk for locoregional tumour recurrence, benefit from perioperative chemotherapy including a neoadjuvant approach. This treatment modality has shown to decrease tumour size and stage and significantly improve progression-free and overall survival. However, neoadjuvant chemotherapy regimens are associated with toxicity and morbidity, and unnecessary treatment should be minimized. Therefore, a reliable pre-therapeutic staging tool for the selection of patients with locoregional advanced tumours is crucial. Our study specifically assessed the diagnostic value of EUS for determining patients' eligibility for neoadjuvant chemotherapy.
Our study showed that TN staging with EUS is feasible in the vast majority of patients with gastroesophageal adenocarcinoma potentially eligible for neoadjuvant chemotherapy. Only in a small minority was T and/or N staging not possible because of tumour stenosis. In our series, a number of patients potentially eligible for neoadjuvant chemotherapy did not undergo EUS because of logistic problems. However, we do not believe that there was a systematic selection of patients who did not undergo EUS and thus it is rather unlikely that our results were biased.
The overall concordance of our EUS results with the individual postoperative pathological T and N stage were 64.9 and 64.7%, respectively. For the locoregional staging of disease our findings correspond to the most recent studies, which could not replicate the excellent results described in the past [18] .
Furthermore, our results emphasize the difficulty in differentiating subserosal from serosal invasion (T2 vs. T3 stage) of a tumour with EUS. In some areas of the stomach and the gastroesophageal junction, the serosa is very fine and therefore even postoperatively it remains sometimes difficult to distinguish between stages pT2 and ≥ pT3. In addition, at the lesser curvature of the stomach there is no serosal layer of the gastric wall and tumours can penetrate directly into the perigastral fatty tissue. In the postoperative histopathological examination, this is often classified as stage pT3, whereas in EUS this is technically stage uT2. For T2 stages, we have seen an EUS accuracy rate of 61.5%, with under-and overestimation of 15.4 and 23.1%. The accuracy rate for determining stage pT3 was 75%, with 25% underestimation. The accuracy rate of the assessment of lymph node invasion was also low, with 50% of nodal positive cases not detected. Thus, the value of EUS in the evaluation of regional lymph node metastasis must be considered questionable.
The main focus of the study was, however, not to evaluate the absolute accuracy of EUS in determining the correct preoperative tumour stage but the reliability of EUS in identifying patients eligible for enrolment in a neoadjuvant chemotherapy protocol. In this regard, it is crucial that EUS correctly identifies patients with stages ≥ pT3 and/or pN+. In this series, the sensitivity, or, in other words, the probability that patients eligible for neoadjuvant chemotherapy were correctly identified by EUS, and the specificity, i.e. the probability that a patient who was not eligible for neoadjuvant chemotherapy was identified as such by Endoscopic ultrasound in the pre-therapeutic staging of gastroesophageal adenocarcinoma: the diagnostic value in defining patients eligible for a neoadjuvant chemotherapy regimen EUS, were both about 76%, which seems acceptable. The positive predictive value, which expresses the probability that a patient identified by EUS as eligible for neoadjuvant chemotherapy met the corresponding histopathological criteria, was 86.4%. It would be desirable to achieve a higher positive prediction for eligibility for a neoadjuvant chemotherapeutic regimen in order to spare patients from undergoing unnecessary chemotherapy. To our knowledge, however, there are no studies assessing which positive predictive values can be achieved with CT or MRI or a multimodal approach in this specific setting. The single modalities do have a similar accuracy for predicting T and N stages [19, 20] , but they have not been evaluated as tools for deciding whether patients should receive neoadjuvant chemotherapy.
Compared to other commonly used diagnostic procedures such as ultrasound, CT and MRI for the detection of colorectal liver metastases [21, 22] , pap smear for the detection of cervical intraepithelial neoplasia [23] or troponin serology for the detection of myocardial ischaemia [24] , the positive predictive value which EUS yielded in our study seems reasonably high. In conclusion, it seems justified to apply neoadjuvant chemotherapy in patients with gastroesophageal adenocarcinoma identified by EUS as eligible because only relatively few patients will be unnecessarily treated and because so far there is no evidence that other diagnostic modalities can identify eligible patients more accurately. This underpins the importance of EUS in the pre-therapeutic staging of gastroesophageal carcinoma. In turn, the negative predictive value, i.e., the probability that a patient identified as not eligible for neoadjuvant treatment by EUS indeed has no tumour invasion into the serosa or lymph nodes, is only 60%, and thus much lower. These results are in accordance with the findings of other authors who have evaluated the value of EUS in the staging of rectal cancer over a 10-year period [25] . They concluded that even though the local tumour staging is underachieved by EUS, the method is still the most accurate staging modality for rectal tumours and allows adequate selection of patients for different therapeutic regimens.
In patients with a "negative" EUS result, the staging needs to be complemented by additional diagnostic modalities such as CT or PET to facilitate the correct identification of patients who meet the inclusion criteria for neoadjuvant chemotherapy. Besides these non-invasive measures, staging laparoscopy seems to be a valuable option in detecting nodal-positive disease and tumours with a deep wall invasion which had remained undiagnosed in imaging procedures [26] . It should also be used in any case of suspected peritoneal metastases to rule out or confirm implants which would preclude a curative approach and thus neoadjuvant treatment.
Conclusions
In summary, our study was able to show that EUS is a feasible and effective staging tool for patients with gastroesophageal adenocarcinoma potentially eligible for neoadjuvant chemotherapy. The exam is able to assess T and N stage in the vast majority of patients. Its positive predictive value for determining locally advanced growth or nodal spread is reasonably high and therefore tumours identified as such by EUS should be treated with neoadjuvant chemotherapy. Because of a lower negative predictive value, tumours identified as strictly confined to the inner layers of the gastroesophageal wall should be reconsidered for additional assessment by cross-sectional imaging, PET or staging laparoscopy.
